WO2020099235A1 - Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3 - Google Patents

Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3 Download PDF

Info

Publication number
WO2020099235A1
WO2020099235A1 PCT/EP2019/080547 EP2019080547W WO2020099235A1 WO 2020099235 A1 WO2020099235 A1 WO 2020099235A1 EP 2019080547 W EP2019080547 W EP 2019080547W WO 2020099235 A1 WO2020099235 A1 WO 2020099235A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
variable domain
human
chain variable
endosialin
Prior art date
Application number
PCT/EP2019/080547
Other languages
English (en)
Inventor
Pier Giorgio NATALI
Mauro Piantelli
Bruno Moncharmont
Stefano Iacobelli
Original Assignee
Mediapharma S.R.L.
Pharmamab Srl
Pharmago Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediapharma S.R.L., Pharmamab Srl, Pharmago Srl filed Critical Mediapharma S.R.L.
Priority to EP19805555.0A priority Critical patent/EP3880706A1/fr
Publication of WO2020099235A1 publication Critical patent/WO2020099235A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Definitions

  • the present invention relates to a bispecific antibody, that specifically binds to both 90K and one of Endosialin and HER-3, a production method therefor, and novel use thereof in the treatment of hyperproliferative diseases such as tumors and metastases thereof.
  • the invention relates to the use of bispecific antibodies able to inhibit the adhesive processes of tumor cells and the angiogenesis in tumors such as breast cancer, ovarian cancer, lung cancer, gastrointestinal cancer, melanoma, lymphoma and other tumors.
  • Cancer is a disease characterized by a series of somatic changes affecting the structure and/or expression of oncogenes and tumor suppressor genes. It is well known that tumor growth beyond diameters of 1 -2 mm depends on formation of new blood vessels, a process known as angiogenesis, as well as on transformation of stromal fibroblasts and extracellular matrix proteins 1 . In vitro and in vivo studies have demonstrated that tumor stroma and vasculature are characterized by a different expression of proteins and receptors if compared to the normal counterparts.
  • an approach to get better specificity to treat cancer or/and neoangiogenesis is the use of antibodies that can target specific antigens expressed in cancer or neo-endothelial cells or precursors that are not expressed or are expressed at a lower level on normal cells.
  • targets can be exploited using antibodies to kill antigen-bearing cells by inhibiting the biological activity of the antigen or by delivering immuno- or radio-conjugates that, when reach the antigen bearing cells, specifically kill these target cells.
  • LGALS3BP Lectin galactoside-binding soluble 3 binding protein
  • 90K is able to specifically bind some ECM proteins, including collagen, fibronectin and laminin [5, 10]. Ulmer et al. (Journal of Cellular Biochemistry, 98:1351-1366 ) discloses that 90K/Mac-2 binding protein contributes to colon cancer progression by modulating tumor cell adhesion to extracellular proteins. In addition, different types of tumor cells start "spreading" as soon as they establish a contact with 90K, similarly to what is observed when cells adhere to the ECM protein laminin [5]. The cellular receptor of 90K responsible for adhesion and spreading has been identified, as beta-1 integrin [5].
  • Tumor cell adhesion to ECM proteins not only favors the processes of migration and cell diffusion, but also preserves cells against apoptosis (also called programmed cell death) caused by antiblastic drugs [1 1 , 12]
  • apoptosis also called programmed cell death
  • Our group observed that when lymphoma tumor cells are maintained in a flask coated with 90K, a binding between the protein and the beta-1 integrin of lymphoma cells takes place and, as a consequence, cells become resistant to the action of antiblastic drugs, as indicated by the reduction of apoptotic cell rate [13].
  • the protective effect of 90K against antiblastic drug induced apoptosis can explain the poor response to chemotherapy and the reduced survival observed in patients affected by lymphoma with elevated blood levels of 90K [13-15].
  • the murine hybridoma cell line from which SP-2 is purified was deposited by Stefano lacobelli at the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH), Mascheroder Weg 1 B D-3300 Braunschweig, Germany under the Budapest Treaty, accession number DSM ACC2116, on Feb. 5, 1993, and at the C.N. CM. (Collection Nationale de Cultures de Microorganismes), Pasteur Institute of Paris, France, accession number 1-1083. SP-2 antibody produced by hybridoma DSM ACC 21 16.
  • the DSM ACC 21 16 monoclonal antibody SP-2 is produced according to the procedures described by Kohler and Milstein, but it may be produced also according to the recombinant DNA technique, using the specific nucleotide sequence of SP-2 or a part thereof.
  • SP-2 (MP-1959) is a murine monoclonal antibody recognizing 90K a glycoprotein secreted in large amounts by the majority of tumor cells, which plays an important role in cell-cell and cell-extracellular matrix adhesion and invasion.
  • Endosialin [16- 18], is a highly restricted 165-kDa cell surface glycoprotein expressed by tumor pericytes and fibroblasts in a broad range of human cancers but not detected in the respective cell types in many normal tissues.
  • the Endosialin cDNA encodes a type I membrane protein of 757 amino acids with a predicted molecular mass of 80.9 kDa.
  • Bioinformatic evaluation classifies Endosialin as a C-type lectin-like protein, composed of a signal leader peptide, five globular extracellular domains (including a C-type lectin domain, one domain with similarity to the Sushi/ccp/scr pattern, and three EGF repeats), followed by a mucin-like region, a transmembrane segment, and a short cytoplasmic tail.
  • Carbohydrate analysis shows that the Endosialin core protein carries abundantly sialylated, O-linked oligosaccharides and is sensitive to O-sialoglycoprotein endopeptidase, placing it in the group of sialomucin-like molecules.
  • Endosialin was demonstrated to interact with proteins of the extracellular matrix (Fibronectin, Collagen I) [19] mediating cell adhesion and migration; another important Endosialin interactor is the tumor secreted protein, 90K [20], a protein involved in cell adhesion and migration, acting also as a pro-angiogenic factor
  • Endosialin/TEM1 The tumor vascular marker Endosialin/TEM1 is emerging as an attractive molecule for diagnostics and therapeutics because of its expression across the stroma of many human tumors, the low to absent expression in normal tissues, and accessibility from the vascular circulation. Smaller scFv constructs have also been reported for Endosialin targeting of drug-delivery vehicles [22] or diagnostics for fluorescence imaging techniques [23].
  • Endosialin is broadly expressed in human cancer [24] Its frequency, extent, and intensity vary among cancer subtypes as well as among individual tumors within subtypes. Endosialin was detected in almost all sarcoma suggesting that the protein is a very frequent feature of sarcoma. In sarcoma, Endosialin was detected in several cellular compartments including malignant sarcoma cells, stromal cells, and vasculature.
  • an Endosialin-targeted therapeutic could have both a direct anticancer effect on malignant sarcoma cells, and an indirect anticancer effect due to antiangiogenic and/or vascular disrupting effects.
  • a diagnostic assay that measures the intensity of Endosialin expression in malignant tissues would assist in selecting patients that could benefit from an anti-Endosialin therapy.
  • Endosialin holds potential value both as a biomarker for certain human cancers, like sarcoma [24-25] and as a targeted therapeutic agent.
  • International application WO 2017/134234 describes the generation of an antibody that specifically recognizes and binds Endosialin.
  • the antibody has the ability to become internalized in Endosialin expressing cells and to block the activation of MAPK in PDGF stimulated human pericytes.
  • the antibody is able to block angiogenesis induced by 90K, a known Endosialin interactor and to inhibit tumor growth alone and in combination with 1959, a humanized antibody against 90K in human osteosarcoma xenograft.
  • the resulting ADC displays potent and antigen dependent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo.
  • ErbB3 receptor also known as HER-3, belongs to the epidermal growth factor receptor tyrosine kinase family (ErbB). This family of receptors consists of four members: ErbB1 (HER1 ), ErbB2 (HER2), ErbB3 (HER-3) and ErbB4 (HER4). Many studies have suggested a critical role for ErbB receptors in cell survival, proliferation and differentiation, as well as in malignant transformation [36, 37] The signal transduction mediated by tyrosine kinase receptors is complex and involves the interaction with two categories of ligands: epidermal growth factor (EGF) and EGF-like ligands (e.g.
  • EGF epidermal growth factor
  • EGF-like ligands e.g.
  • TGFa and amphiregulin TGFa and amphiregulin
  • NGF Neuregulin
  • HRG Heregulin
  • NDF Neu Differentiation Factor
  • ErbB2 is the preferred heterodimerization partner of the other ErbB receptors, including ErbB1 (activated by EGF or EGF-like ligands), and ErbB3 and ErbB4 (activated by neuregulin, NRG).
  • ErbB1 activated by EGF or EGF-like ligands
  • ErbB3 and ErbB4 activated by neuregulin, NRG.
  • the two major signaling pathways activated by ErbB receptors are Ras-Raf- MAPK and PI3K-AKT pathways.
  • ErbB2 gene is amplified in 20 to 30% of breast cancers and is correlated with a poor prognosis.
  • ErbB3 receptor has also been shown to be overexpressed in breast cancer patients. High levels of expression of both ErbB2 and ErbB3 receptors are associated with an aggressive biology of tumor.
  • ErbB2/ ErbB3 heterodimers deliver the most potent and long-lasting proliferative intracellular signal among the possible combinations of pairs of ErbB family members [38-41]
  • Several studies have suggested an important role of ErbB3 receptor in progression of many human tumor types, such as prostate cancer, melanoma, and gastric carcinoma.
  • Tumor cells often upregulate different growth-promoting receptors that can act either independently or crosstalk intra- cellularly. Targeting of one receptor by a mono-specific antibody may result in resistance which is associated with the upregulation of alternative receptors as well as pathway switching (Kontermann (2012) mAbs 4:2, 182-197), indicating that it may be beneficial to target or block multiple cell surface antigens (targets) on a tumor cell.
  • novel bispecific antibodies have been developed, that are significantly more effective in the treatment of cancer than previously known monospecific antibodies and even combinations of monospecific antibodies.
  • the present invention provides a bispecific antibody comprising a first antigen binding domain that binds to 90K and a second antigen binding domain that binds Endosialin or HER-3.
  • the bispecific antibody further comprises a third antigen binding domain.
  • a trispecific antibody comprising antigen binding domains for 90K, Endosialin and HER-3 can be provided.
  • the bispecific antibody provided in the present invention preferably comprises a variable domain fragment of an antibody that specifically binds to human 90K and a variable domain fragment of an antibody that specifically binds to human Endosialin or a variable domain fragment of an antibody that specifically binds to HER-3.
  • a heavy chain variable domain in the variable domain fragment of the antibody that specifically binds to human 90K is adjacent to a heavy chain variable domain in the variable domain fragment of the antibody that specifically binds to human Endosialin or HER-3, or a light chain variable domain in the variable domain fragment of the antibody that specifically binds to human 90K is adjacent to a light chain variable domain in the variable domain fragment of the antibody that specifically binds to human Endosialin or HER-3.
  • the bispecific antibody has, from an N-terminus to a C-terminus, an arrangement of: light chain variable region and heavy chain variable region of the antibody that specifically binds to human 90K, and then heavy chain variable region and light chain variable region of the antibody that specifically binds to human Endosialin or HER-3, or heavy chain variable region and light chain variable region of the antibody that specifically binds to human 90K, and then light chain variable region and heavy chain variable region of the antibody that specifically binds to human Endosialin or HER-3.
  • variable domain of the 90K antibody can be derived from the variable domain of any known 90K antibody, preferably from the sequence of the monoclonal antibody 1959.
  • 1959 is a humanized anti-90K antibody of the isotype lgG1 that is characterized by a heavy chain variable region including the CDR sequences of the SEQ ID NOs. 1 -3 and light chain variable region comprising the CDR sequences of SEQ ID NOs. 4-6.
  • the variable domain of the Endosialin antibody can be derived from the variable domain of any known Endosialin antibody, preferably from the sequence of the monoclonal antibody E-8.3.
  • E-8.3 is a humanized anti-Endosialin antibody of the isotype lgG1 that is characterized by a heavy chain variable region including the CDR sequences of the SEQ ID NOs. 7-9 and light chain variable region comprising the CDR sequences of SEQ ID NOs. 10-12.
  • variable domain of the HER-3 antibody can be derived from the variable domain of any known HER-3 antibody, preferably from the sequence of the monoclonal antibody EV20.
  • EV20 is a humanized anti-HER-3 antibody of the isotype lgG1 that is characterized by a heavy chain variable region including the CDR sequences of the SEQ ID NOs. 13-15 and light chain variable region comprising the CDR sequences of SEQ ID NOs. 16-18.
  • the bispecific antibody comprises an lgG1-type antibody targeting the first antigen (90K) fused with a scFv fragment targeting the second antigen (Endosialin or HER-3).
  • the bispecific antibody may comprise an lgG1 -type antibody targeting the second antigen (Endosialin or HER-3)) fused with a scFv fragment targeting the first antigen (90K).
  • a further aspect of the invention is a nucleic acid molecule encoding the bispecific antibody, optionally in operative linkage to an expression control sequence.
  • a further aspect of the invention is a host, in particular a recombinant cell which comprises the nucleic acid molecule.
  • the cell may be used for the preparation of the antibody.
  • composition comprising the antibody, the nucleic acid molecule or the host, optionally, together with a pharmaceutical acceptable carrier.
  • Still a further aspect of the invention is a method for the prevention or treatment of neoplastic diseases and cancer.
  • the present invention provides a bispecific antibody, which comprises a protein functional domain targeting a first antigen 90K and a protein functional domain targeting a second antigen which is selected from Endosialin and HER-3.
  • the protein functional domain targeting the first antigen 90K is operably linked to the protein functional domain targeting the second antigen Endosialin or HER-3, while their respective spatial structures are maintained and their respective physiological activities are retained.
  • the protein functional domain targeting the first antigen 90K and the protein functional domain targeting the second antigen Endosialin or HER-3 can be fused together directly without affecting their respective functions.
  • the protein functional domain targeting the second antigen may be linked to the N terminus or C terminus of the protein functional domain targeting the first antigen 90K directly or with an additional spacer such as a linker therebetween.
  • both the heavy chain variable domain and the light chain variable domain of the protein functional domain targeting the first antigen 90K may be located at the N terminus of the protein functional domain targeting the first antigen 90K; and both the heavy chain variable domain and the light chain variable domain of the protein functional domain targeting the second antigen Endosialin or HER-3 may be located at the N terminus of the protein functional domain targeting the second antigen Endosialin or HER-3.
  • variable domain fragment of the antibody that specifically binds to human 90K comprises a heavy chain variable region comprising the CDR sequences as shown in SEQ ID NOs: 1-3 and a light chain variable region comprising the CDR sequences as shown in SEQ ID NOs: 4-6.
  • the variable domain fragment of the antibody that specifically binds to human Endosialin preferably comprises a heavy chain variable region comprising the CDR sequences as shown in SEQ ID NOs: 7-9 and a light chain variable region comprising the CDR sequences as shown in SEQ ID NO: 10-12.
  • variable domain fragment of the antibody that specifically binds to human HER-3 preferably comprises a heavy chain variable region comprising the CDR sequences as shown in SEQ ID NOs: 13-15 and a light chain variable region comprising the CDR sequences as shown in SEQ ID NOs: 16-18.
  • the bispecific antibody comprises an lgG1-type antibody targeting the first antigen (90K) fused with a scFv fragment targeting the second antigen (Endosialin or HER-3).
  • the bispecific antibody may comprise an lgG1 -type antibody targeting the second antigen (Endosialin or HER-3)) fused with a scFv fragment targeting the first antigen (90K).
  • the anti-Endosialin antibody E-8.3 is fused with the anti-90K antibody 1959, such that a fusion is made between the whole lgG1 of one antibody and the scFv of the second antibody.
  • 1959-scFv VH-VL
  • An especially preferred anti- 90K/anti-Endosialin-antibody with this arrangement comprises a heavy chain amino acid sequence as shown in SEQ ID NO:19 and a light chain amino acid sequence as shown in SEQ ID NO:20.
  • E-8.3-scFv (VH-VL) can be fused to the C-terminal of the heavy chain of 1959-lgG1.
  • VH-VL E-8.3-scFv
  • An especially preferred anti-90K/anti-Endosialin-antibody with this arrangement comprises a heavy chain amino acid sequence as shown in SEQ ID NO:21 and a light chain amino acid sequence as shown in SEQ ID NO:22.
  • the anti-HER-3 antibody EV20 is fused with the anti- 90K antibody 1959, such that a fusion is made between the whole lgG1 of one antibody and the scFv of the second antibody.
  • 1959-scFv VH-VL
  • EV20-scFv VH-VL
  • EV20-scFv VH-VL
  • Bispecific in the term“bispecific antibody’ as used herein refers to specifically targeting two different antigens at the same time.
  • the two different antigens are 90K and one of Endosialin and HER-3, respectively.
  • the bispecific antibody of the present invention is capable to inhibit to a greater extent tumor angiogenesis if compared to the effect of the single antibody treatments.
  • the bispecific antibody at the same time inhibits adhesive processes of tumor cells and inhibits angiogenesis of tumor cells and pericytes.
  • antibody particularly refers to molecules comprising at least one immunoglobulin heavy chain and at least one immunoglobulin light chain.
  • Each heavy and light chain may comprise a variable and a constant domain.
  • the antigen binding site may be formed from the variable domains of a heavy and light chain.
  • a variable region (also referred to as variable domain) comprises complementarity determining regions (CDRs), e.g. a CDR1 , a CDR2 and a CDR3 region and framework regions (FRs) flanking the CDRs.
  • CDRs complementarity determining regions
  • variable domain refers to the stretches of amino acids within the variable domain of an antibody that primarily make contact with the antigen and determined antibody specificity. This region is also known as the hypervariable region.
  • the invention also encompasses fragments of antibodies, e.g. portions of the above- mentioned bispecific antibodies which comprise at least two antigen binding sites, one of 90K and the other for Endosialin or HER-3.
  • antibody fragments include Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, diabodies, scFv fragments, single chain antibody molecules, small modular immunopharmaceuticals (SMIPs), affibodies, avimers, nanobodies, domain antibodies and other fragments as long as they exhibit the desired capability of binding to 90K and one of Endosialin and HER-3.
  • SMIPs small modular immunopharmaceuticals
  • a bispecific antibody according to the preferred embodiments of the present invention comprises the whole IgG of one antibody and a scFv fragment of the other antibody.
  • Avimer relates to a multimeric binding protein or peptide engineered using, for example, in vitro exon shuffling and phage display. Multiple binding domains are linked, resulting in greater affinity and specificity compared to single epitope immunoglobulin domains.
  • Nanobody or single domain antibody relates to an antibody fragment consisting of a single monomeric variable antibody domain.
  • Affibody molecules are small high affinity proteins being engineered to bind specifically to a large number of target proteins.
  • Diabodies are antibody fragments with two antigen binding sites that may be bivalent or bispecific. See for example Hudson et al., (2003). Single-chain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all, or a portion of the light chain variable domain of an antibody. Antibody fragments can be made by various techniques including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant hosts (e.g. E. coli or phage) as described herein.
  • Multispecific antibodies include but are not limited to recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities and“knob in hole” engineering.
  • Multispecific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc- heterodimeric molecules; crosslinking two or more antibodies or fragments; using leucine zippers to produce bispecific antibodies; using“ diabody” technology for making bispecific antibodies and using single-chain Fv and preparing trispecific antibodies as described.
  • Engineered antibodies with three or more functional antigen binding sites including “octopus antibodies” are also included herein.
  • amino acid sequence variants of the antibodies provided herein are contemplated as long as they exhibit the desired capability of binding to 90K and at least one of Endosialin and HER-3. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
  • Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g. antigen binding.
  • bind or“ binding” of an antibody means an at least temporary interaction or association with or to a target antigen, i.e. 90K, Endosialin and HER-3, comprising fragments thereof containing an epitope.
  • a target antigen i.e. 90K, Endosialin and HER-3, comprising fragments thereof containing an epitope.
  • a particular binding epitope is a conformational epitope between residues 107 and 435 of the amino acid sequence of the 90K protein.
  • Endosialin a particular binding epitope is between amino acids 477-488 of human Endosialin.
  • a bispecific antibody provided herein has a dissociation constant (Kd) for 90K, Endosialin, and/or HER-3 of ⁇ 1 mM, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 8 M or less, e.g. from 10 8 M to 10 13 M, e.g. 10 9 M to 10 13 M).
  • Kd dissociation constant
  • Kd is measured by a radio-labeled antigen binding assay (Radioimmunoassay, RIA) performed with the Fab version of an antibody of interest and its antigen.
  • Radioimmunoassay Radioimmunoassay, RIA
  • Kd is measured using surface plasmon resonance assays with immobilized antigen.
  • the antibodies are human monoclonal antibodies directed against an epitope of human 90K and against an epitope of human Endosialin or human HER-3 as described herein.
  • the antibody may be any antibody of natural and/or synthetic origin, e.g. an antibody of mammalian origin.
  • the constant domain -if present- is a human constant domain.
  • the variable domain is preferably a mammalian variable domain, e.g. a humanized or a human variable domain.
  • Antibodies according to the invention are preferably monoclonal antibodies.
  • antibodies of the present invention are preferably recombinant murine antibodies, chimeric, humanized or fully human antibodies, or fragments thereof.
  • Monoclonal antibodies may be produced by any suitable method such as that of Kohler and Milstein [55] or by recombinant DNA methods. Monoclonal antibodies may also be isolated from phage antibody libraries using techniques described in Clackson et al [56].
  • the antibodies of the invention are humanized antibodies, in particular fully human antibodies.
  • Humanized forms of the antibodies may be generated according to the methods known in the art such as chimerization or CDR grafting. Alternative methods for the production of humanized antibodies are well known in the art and are described in, e.g., EP-A1 0 239 400 and WO 90/07861. Human antibodies can also be derived by in vitro methods. Suitable examples include but are not limited to phage display, yeast display, and the like.
  • chimeric antibody relates to antibodies comprising polypeptides from different species, such as, for example, mouse and human.
  • the production of chimeric antibodies is described, for example, in WO 89/09622.
  • the antibody of the invention may be preferably of the lgG1 , lgG2, lgG3, lgG4, IgM, lgA1 , lgA2, IgAsec, IgD, and IgE antibody-type. It will be appreciated that antibodies that are generated need not initially possess such an isotype but, rather the antibody as generated can possess any isotype and that the antibody can be isotype-switched.
  • the antibodies or antibody fragments of the invention are optionally deimmunized for therapeutic purposes.
  • the antibodies of the invention can be further coupled to other moieties for, e.g., drug targeting and imaging applications.
  • Antibodies coupled to other moieties are also called "antibody conjugates”. Coupling may be conducted chemically after expression of the antibody or antigen to site of attachment or the coupling product may be engineered into the antibody or antigen of the invention at the DNA level.
  • the antibody or antibody fragment of the invention may be labelled, i.e. coupled to a labelling group. Suitable labels include radioactive labels, fluorescent labels, suitable dye groups, enzyme labels, chromogenes, chemiluminescent groups, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter etc.
  • the labels are covalently bound to the antibody.
  • labelled antibodies or antibody fragments may in particular be used in immunohistochemistry assays or for molecular imaging in vivo.
  • the antibody or antibody fragment of the invention may be conjugated with an effector group, in particular a therapeutic effector group such as a cytotoxic agent or a radioactive group agent.
  • an effector group in particular a therapeutic effector group such as a cytotoxic agent or a radioactive group agent.
  • the bispecific antibody of the present invention may optionally be coupled to a labeling group and/or to an effector group, preferably a therapeutic group.
  • the antibody is linked to a paramagnetic, radioactive or fluorogenic ion that is detectable upon imaging. This type of antibody is particularly suitable for diagnostic use.
  • the antibody is linked to an anticellular agent, preferably in the form of anti-mitotic or DNA damaging agents capable of killing or suppressing the growth or cell division of tumor cells.
  • the anticellular agent may, for example, comprise a chemotherapeutic agent, radioisotope or cytotoxin.
  • anticellular agents comprise an antimetabolite, an anthracycline, a vinca alkaloid, an antibiotic, an alkylating agent or a plant-, fungus- or bacteria-derived toxin.
  • An exemplary DNA damaging agent that may be linked to the antibody of the invention is a Minor Grove Binder duocarmycin derivative.
  • Cytotoxins suitable to be linked to the antibody of the invention may, for example, comprise an A chain toxin, a ribosome inactivating protein, a- sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin or Pseudomonas exotoxin. Further, the cytotoxin may comprise deglycosylated ricin A chain.
  • Labelling groups or effector groups may be attached by linkers (spacer arms) of various lengths to reduce potential steric hindrance. Effector groups may be also attached directly to the antibody.
  • the present invention relates to a nucleic acid molecule encoding the bispecific antibody of the invention or fragment thereof or a nucleic acid capable of hybridizing thereto under stringent conditions.
  • the nucleic acid molecule of the invention encoding the above-described antibody, antibody fragment or derivative thereof may be, e.g. DNA, cDNA, RNA or synthetically produced DNA or RNA or recombinantly produced chimeric nucleic acid molecule comprising any of those nucleic acid molecules either alone or in combination.
  • the nucleic acid molecule may also be genomic DNA corresponding to the entire gene or a substantial portion thereof or to fragments and derivatives thereof.
  • the nucleotide sequence may correspond to the naturally occurring nucleotide sequence or may contain single or multiple nucleotide substitutions, deletions or additions.
  • the nucleic acid molecule is a cDNA molecule.
  • an isolated nucleic acid molecule of the present invention is particularly selected from the group consisting of:
  • hybridizing under stringent conditions means that two nucleic acid fragments hybridize with one another under standardized hybridization conditions as described for example in Sambrook et al., "Expression of cloned genes in E. coli” in Molecular Cloning: A laboratory manual (1989), Cold Spring Harbor Laboratory Press, New York, USA.
  • Such conditions are for example hybridization in 6.0xSSC at about 45° C. followed by a washing step with 2.0xSSC at 50° C, preferably 2.0xSSC at 65°C, or 0.2xSSC at 50°C, preferably 0.2xSSC at 65°C.
  • a vector comprising a nucleic acid molecule of the invention.
  • Said vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective.
  • the vector of the invention is an expression vector wherein the nucleic acid molecule is operatively linked to one or more control sequences allowing the transcription and optionally expression in prokaryotic and/or eukaryotic host cells.
  • the invention further relates to a host comprising the vector of the invention.
  • Said host may be a prokaryotic or eukaryotic cell or a non-human transgenic animal.
  • the polynucleotide or vector of the invention which is present in the host may either be integrated into the genome of the host or it may be maintained extra chromosomally.
  • the host can be any prokaryotic or eukaryotic cell, such as a bacterial, insect, fungal, plant, animal, mammalian or, preferably, human cell.
  • Preferred fungal cells are, for example, those of the genus Saccharomyces, in particular those of the species S. cerevisiae.
  • the invention additionally relates to a method for the preparation of an antibody, comprising culturing the host of the invention under conditions that allow synthesis of said antibody and recovering said antibody from said culture.
  • a further aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the bispecific antibody of the invention or a fragment thereof, the nucleic acid molecule, the vector, the host of the invention or an antibody obtained by a method of the invention.
  • composition as employed herein comprises at least one compound of the invention.
  • a composition is a therapeutic/pharmaceutical or a diagnostic composition.
  • the diagnostic composition of the invention may be used for assessing the onset or the disease status of a cancer.
  • composition preferably comprises a pharmaceutically acceptable carrier, diluent and/or excipient.
  • Suitable pharmaceutical carriers, excipients and/or diluents are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers, excipients and/or diluents can be formulated by well-known conventional methods.
  • compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intra-bronchial administration. Preferred is an intravenous, intramuscular and/or subcutaneous administration.
  • These pharmaceutical compositions can be administered to the subject at a suitable dose.
  • the dosage regimen can be determined by the attending physician and clinical factors.
  • compositions of the invention may be administered locally or systemically.
  • Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or' fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • the pharmaceutical composition of the invention may comprise further agents depending on the intended use of the pharmaceutical composition.
  • composition comprises a further active agent, such as a further antibody or antibody fragment.
  • composition of the invention is used in combination with at least one further antineoplastic agent.
  • Said combination is effective, for example, in inhibiting abnormal cell growth.
  • antineoplastic agents are presently known in the art.
  • the term includes all agents that are capable of prevention, alleviation and/or treatment of hyperproliferative disorders, especially cancer.
  • the antineoplastic agent is selected from the group consisting of antibodies, small molecules, antimetabolites, alkylating agents, topo-isomerase inhibitors, microtubule-targeting agents, kinase inhibitors, protein synthesis inhibitors, immuno- therapeutics, hormones or analogs thereof.
  • antineoplastic agents which can be used in combination with the antibodies provided herein include, for example, chemotherapeutic agents such as Paclitaxel, Anthracyclines, Fluoropirimidine, vinca alkaloids, platinum salts, in particular capecitabine, daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis- chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea
  • compositions of the invention may be administered in combination with a further therapeutic composition comprising an active agent as described above and/or irradiation and/or radiotherapy.
  • compositions of the invention are for the use in treating and/or preventing diseases wherein inhibition of angiogenesis is helpful, in particular neoplastic diseases or cancer.
  • the compositions may also be used for the manufacture of a medicament for treating and/or preventing diseases wherein inhibition of angiogenesis is helpful, in particular neoplastic diseases or cancer.
  • Tumors to be treated are for example breast cancer, ovarian cancer, lung cancer, gastrointestinal cancer, melanoma, lymphoma and metastases thereof.
  • the invention further relates to a method of treating a disease wherein the antibody of the invention is administered to a mammal and wherein said disease is cancer or any other disease wherein inhibition of angiogenesis is helpful.
  • Figure 1 illustrates bispecific antibody constructs obtained by fusing anti-human
  • Endosialin E-8.3 with anti-human 90K wherein the lgG1 of one antibody is fused to the scFv of the other antibody.
  • Mac-2 binding protein is a cell- adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds b1 integrins, collagens and fibronectin.
  • Rea A Calmieri G, Tinari N, Natoli C, Tagliaferro P, Morabito A, Grassadonia A, Bianco AR, lacobelli S. 90K is a serum marker of poor prognosis in non-Hodgikin's lymphoma patients. Oncol Rep 1994;723-5.
  • Tumor stroma marker endosialin (Tem1 ) is a binding partner of metastasis-related protein Mac-2 BP/90K.
  • LGALS3BP lectin galactoside- binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes
  • Rouleau C Sancho J, Campos-Rivera J, Teicher BA. Endosialin expression inside populations in human sarcoma cell lines. Oncol Lett. 2012 Feb; 3(2):325-329.
  • Rouleau C Smale R, Sancho J, Fu YS, Kurtzberg L, Weber W, Kruger A, Jones C, Roth S, Bormann C, Dunham S, Krumbholz R, Curiel M, Wallar G, Mascarello J, Campos-Rivera J, Horten B, Schmid S, Miller G, Teicher BA. Endosialin: a novel malignant cell therapeutic target for neuroblastoma. Int J Oncol.
  • ERBB3 is requie for the maintenance of neuregulin-depndent and -independent attributes of malignant progression in prostate cancer cells. Int.J. Cancer 125,2565- 75 (2009). 48. D.F. Stem, ERBB3/ERBB3 and ERBB2/ERBB2 duet in mammamry development and breast cancer. J Mammary Gland Biol Neoplasia. 13, 215-23 (2008).
  • ErbB2/ErbB3 heterodimer functions a san oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un anticorps bispécifique, qui se lie de manière spécifique à la fois à 90K et à l'un parmi l'endosialine et HER-3, un procédé de production associé, et une nouvelle utilisation correspondante dans le traitement de maladies hyperprolifératives telles que des tumeurs et des métastases associées. En particulier, l'invention concerne l'utilisation d'anticorps bispécifiques capables d'inhiber les processus d'adhésion de cellules tumorales et l'angiogenèse dans des tumeurs tel que le cancer du sein, le cancer de l'ovaire, le cancer du poumon, le cancer gastro-intestinal, le mélanome, le lymphome, et d'autres tumeurs.
PCT/EP2019/080547 2018-11-12 2019-11-07 Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3 WO2020099235A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19805555.0A EP3880706A1 (fr) 2018-11-12 2019-11-07 Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18205660.6 2018-11-12
EP18205660 2018-11-12

Publications (1)

Publication Number Publication Date
WO2020099235A1 true WO2020099235A1 (fr) 2020-05-22

Family

ID=64277570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/080547 WO2020099235A1 (fr) 2018-11-12 2019-11-07 Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3

Country Status (2)

Country Link
EP (1) EP3880706A1 (fr)
WO (1) WO2020099235A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3995829A1 (fr) * 2020-11-09 2022-05-11 MediaPharma S.r.l. Lgals3bp en tant que biomarqueur diagnostique, pronostique et thérapeutique du covid-19 et autres maladies dues à un choc cytokinique

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400A2 (fr) 1986-03-27 1987-09-30 Medical Research Council Anticorps recombinants et leurs procédés de production
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
WO1993016180A2 (fr) 1992-02-17 1993-08-19 Max Planck Gesellschaft Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95)
WO2010097825A1 (fr) 2009-02-25 2010-09-02 Stefano Iacobelli Utilisation d'anticorps monoclonaux anti-90k pour la prévention et le traitement de tumeurs et des métastases de celles-ci
WO2012052230A1 (fr) 2010-10-18 2012-04-26 Mediapharma S.R.L. Anticorps se liant à erbb3
EP3202788A1 (fr) * 2016-02-05 2017-08-09 MediaPharma S.r.l. Anticorps à liaison d'endosialin
WO2017189959A1 (fr) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
WO2019197651A1 (fr) * 2018-04-12 2019-10-17 Mediapharma S.R.L. Conjugué anticorps de lgals3bp-médicament et son utilisation pour le traitement du cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400A2 (fr) 1986-03-27 1987-09-30 Medical Research Council Anticorps recombinants et leurs procédés de production
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
WO1990007861A1 (fr) 1988-12-28 1990-07-26 Protein Design Labs, Inc. IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2
WO1993016180A2 (fr) 1992-02-17 1993-08-19 Max Planck Gesellschaft Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95)
WO2010097825A1 (fr) 2009-02-25 2010-09-02 Stefano Iacobelli Utilisation d'anticorps monoclonaux anti-90k pour la prévention et le traitement de tumeurs et des métastases de celles-ci
WO2012052230A1 (fr) 2010-10-18 2012-04-26 Mediapharma S.R.L. Anticorps se liant à erbb3
EP3202788A1 (fr) * 2016-02-05 2017-08-09 MediaPharma S.r.l. Anticorps à liaison d'endosialin
WO2017134234A1 (fr) 2016-02-05 2017-08-10 Mediapharma S.R.L. Anticorps se liant à l'endosialine
WO2017189959A1 (fr) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
WO2019197651A1 (fr) * 2018-04-12 2019-10-17 Mediapharma S.R.L. Conjugué anticorps de lgals3bp-médicament et son utilisation pour le traitement du cancer

Non-Patent Citations (63)

* Cited by examiner, † Cited by third party
Title
A JEMALR SIEGELE WARD ET AL.: "Cancer Statistics", CA CANCER J CLIN, vol. 59, no. 2009, 2009, pages 225 - 49
ALIMANDI MROMANO ACURIA MCMURARO R ET AL.: "Cooperative siganling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas", ONCOGENE, vol. 10, no. 9, 1995, pages 1813 - 21
ALIMANDI MWANG LMBOTTARO D ET AL.: "Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors", EMBO J, vol. 16, no. 18, 1997, pages 5608 - 17
B. TANNERD HASENCLEVERK STERN ET AL.: "ErbB3 predicts survival in Ovarian cancer", J.CIIN.ONCO., vol. 24, 2006, pages 17 - 23
BAGLEY RG: "Endosialin: from vascular target to biomarker for human sarcomas", BIOMARK MED., vol. 3, no. 5, October 2009 (2009-10-01), pages 589 - 604, XP009155109
BRIAN TOMKOWICZKATHERINE RYBINSKIBRIAN FOLEYWOLFGANG EBELBRAD KLINEERIC ROUTHIERPHILIP SASSNICHOLAS CNICOLAIDES, LUIGI GRASSOYUHON: "Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration", PROC NATL ACAD SCI USA., vol. 104, no. 46, 13 November 2007 (2007-11-13), pages 17965 - 17970, XP002494741, DOI: 10.1073/pnas.0705647104
BROWNE BCO'BRIEN NDUFFY ET AL.: "HER-2 signaling and inhibition in breast cancer", CURR CANCER DRUG TARGETS, vol. 9, no. 3, 2009, pages 419 - 38
CARSON-WALTER EBWINANS BNWHITEMAN MCLIU YJARVELA SHAAPASALO HTYLER BMHUSO DLJOHNSON MDWALTER KA: "Characterization of TEM1/endosialin in human and murine brain tumors", BMC CANCER, vol. 9, 30 November 2009 (2009-11-30), pages 417, XP021066985, DOI: 10.1186/1471-2407-9-417
CHAMBERS AFGROOM ACMACDONALD IC: "Dissemination and growth of cancer cells in metastatic sites", NAT REV CANCER, vol. 2, 2002, pages 563 - 72
CHRISTIAN SAHORN HKOEHLER AEISENHABER FRODI HPGARIN- CHESA PPARK JERETTIG WJLENTER MC, J BIOL CHEM., vol. 276, no. 10, 9 March 2001 (2001-03-09), pages 7408 - 14
CLACKSON THOOGENBOOM HRGRIFFITHS ADWINTER G: "Making antibody fragments using phage display libraries", NATURE, vol. 352, no. 6336, 1991, pages 624 - 8, XP002101159, DOI: 10.1038/352624a0
D.F. STERN: "ERBB3/ERBB3 and ERBB2/ERBB2 duet in mammamry development and breast cancer", J MAMMARY GLAND BIOL NEOPLASIA, vol. 13, 2008, pages 215 - 23, XP019609080
DAMIANO JSCRESS AEHAZLEHURST LASHTIL AADALTON WS: "Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines", BLOOD, vol. 93, 1999, pages 1658
D'OSTILIO NSABATINO GNATOLI CULLRICH ALACOBELLI S: "90K (Mac-2 BP) in human milk", CLIN EXP IMMUNOL, vol. 104, 1996, pages 543 - 6
ENZA PICCOLO ET AL: "LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, vol. 91, no. 1, 5 August 2012 (2012-08-05), pages 83 - 94, XP035158841, ISSN: 1432-1440, DOI: 10.1007/S00109-012-0936-6 *
FORNARINI BD'AMBROSIO CNATOLI CTINARI NSILINGARDI VLACOBELLI S: "Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo", BLOOD, vol. 96, 2000, pages 3282 - 5
GRASSADONIA ATINARI NLURISCI IPICCOLO ECUMASHI AINNOMINATO PD'EGIDIO MNATOLI CPIANTELLI MLACOBELLI S: "90K (Mac-2 BP) and galectins in tumor progression and metastasis", GLYCOCONJ J, vol. 19, 2004, pages 551 - 6, XP019206944, DOI: 10.1023/B:GLYC.0000014085.00706.d4
HARARI DYARDEN Y: "Molecular mechanisms underlying ErbB2/ERBB2 action in breast cancer", ONCOGENE, vol. 19, no. 53, 2000, pages 6102 - 14, XP002479573, DOI: 10.1038/sj.onc.1203973
HUDSON ET AL., NAT. MET., vol. 9, 2003, pages 129 - 134
INOHARA HAKAHANI SKOTHS KRAZ A: "Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion", CANCER RES, vol. 56, 1996, pages 4530 - 4
J.A. ENGELMANK. ZEJNULLAHUT MITSUDOMI ET AL.: "MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 signalling", SCIENCE, vol. 316, 2007, pages 1039 - 43, XP002498405, DOI: 10.1126/science.1141478
J.BASELGAS.M. SWAIN: "Novel anticancer targets: revisiting ERBB2 and discovering ERBB3", NAT.REV.CANCER., vol. 9, 2009, pages 463 - 75, XP009139034, DOI: 10.1038/nrc2656
KOHLER GMILSTEIN C: "Continuous cultures of fused cells secreting antibody of predefined specificity", NATURE, vol. 256, 1975, pages 495 - 497, XP002024548
KOTHS KTAYLOR EHALENBECK RCASIPIT CWANG A: "Cloning and characterization of a human Mac-2-binding protein, a newmember of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain", J BIOL CHEM, vol. 268, 1993, pages 14245 - 9, XP002914299
L.M. WEINERM.V. DHODAPKARS. FERRONE, MONOCLONAL ANTIBODIES FOR CANCER IMMUNOTHERAPY
LACOBELLI SARNO ED'ORAZIO ACOLETTI G: "Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cance", CANCER RES, vol. 46, 1986, pages 3005 - 10
LACOBELLI SARNO ESISMONDI PNATOLI CGENTILONI NSCAMBIA GGIAI MCORTESE PPANICI PBMANCUSO S: "Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients", BREAST CANCER RES TREAT, vol. 11, 1988, pages 19 - 30
M. SOLERF MANICNIO.MECA-CORTES ET AL.: "ERBB3 is requie for the maintenance of neuregulin-depndent and -independent attributes of malignant progression in prostate cancer cells", INT.J. CANCER, vol. 125, 2009, pages 2565 - 75
M.R. FREEMAN: "HER-2/ERBB3 heterodimers in prostate cancer: Whither HER1/ EGFR?", CANCER CELL, vol. 6, 2004, pages 427 - 428
M.RESCHKED.MIHIC-PROBSTE.H. VAN DER HORST ET AL.: "ERBB3 is a determinant for poor prognosis in Melanoma", CLIN. CANE. RES., vol. 14, 2008, pages 5188 - 97, XP002504884, DOI: 10.1158/1078-0432.CCR-08-0186
MAIA MDEVRIESE AJANSSENS TMOONS MLORIES RJTAVERNIER JCONWAY EM: "CD248 facilitates tumor growth via its cytoplasmic domain", BMC CANCER, vol. 11, 8 May 2011 (2011-05-08), pages 162, XP021099965, DOI: 10.1186/1471-2407-11-162
MARTY CLANGER-MACHOVA ZSIGRIST SSCHOTT HSCHWENDENER RABALLMER-HOFER K: "Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy", CANCER LETT., vol. 235, 2006, pages 298 - 308, XP026236325, DOI: 10.1016/j.canlet.2005.04.029
MEHLEN PPUISIEUX A: "Metastasis: a question of life or death", NAT REV CANCER, vol. 6, 2006, pages 449 - 58, XP009139252, DOI: 10.1038/nrc1886
N.E. HYNES: "Targeting ERBB receptors in cancer", RECENT RESULTS CANCER RES., vol. 172, 2007, pages 45 - 57
N.E. HYNESH.A. LANE: "ERBB receptors and cancer: the complexity of targeted inhibitors", NAT REV CANCER, vol. 5, 2005, pages 341 - 54, XP002362804, DOI: 10.1038/nrc1609
N.E. HYNESMACDONALD G: "rbB receptors and signaling pathways in cancer", CURR OPIN CELL BIOL, vol. 21, no. 2, 2009, pages 177 - 84
OZAKI ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 317, 2004, pages 1089 - 1095
PICCOLO ET AL., J MOL MED, vol. 91, 2013, pages 83 - 94
PICCOLO ETINARI NSEMERARO DTRAINI SFICHERA ICUMASHI ALA SORDA RSPINELLA FBAGNATO ALATTANZIO R: "LGALS3BP, lectin galactoside- binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis", J MOL MED (BERL, vol. 91, no. 1, January 2013 (2013-01-01), pages 83 - 94, XP035158841, DOI: 10.1007/s00109-012-0936-6
REA ACALMIERI GTINARI NNATOLI CTAGLIAFERRO PMORABITO AGRASSADONIA ABIANCO ARLACOBELLI S: "90K is a serum marker of poor prognosis in non-Hodgikin's lymphoma patients", ONCOL REP, 1994, pages 723 - 5
RENATE BECKERMARTIN C LENTERTOBIAS VOLLKOMMERANJA M BOOSDENNIS PFAFFHELLMUT G AUGUSTINSVEN CHRISTIAN: "Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K", FASEB J, vol. 22, no. 8, 19 August 2008 (2008-08-19), pages 3059 - 67
RETTIG WJGARIN-CHESA PHEALEY JHSU SLJAFFE EAOLD LJ: "Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer", PROC NATL ACAD SCI USA., vol. 89, no. 22, 15 November 1992 (1992-11-15), pages 10832 - 6, XP002294706, DOI: 10.1073/pnas.89.22.10832
ROULEAU CCURIEL MWEBER WSMALE RKURTZBERG LMASCARELLO JBERGER CWALLAR GBAGLEY RHONMA N: "Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma", CLIN CANCER RES., vol. 14, no. 22, 15 November 2008 (2008-11-15), pages 7223 - 36, XP055363903, DOI: 10.1158/1078-0432.CCR-08-0499
ROULEAU CSANCHO JCAMPOS-RIVERA JTEICHER BA: "Endosialin expression inside populations in human sarcoma cell lines", ONCOL LETT., vol. 3, no. 2, February 2012 (2012-02-01), pages 325 - 329
ROULEAU CSMALE RFU YSHUI GWANG FHUTTO EFOGLE RJONES CMKRUMBHOLZ RROTH S: "Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling", INT J ONCOL., vol. 39, no. 1, July 2011 (2011-07-01), pages 73 - 89
ROULEAU CSMALE RSANCHO JFU YSKURTZBERG LWEBER WKRUGER AJONES CROTH SBORMANN C: "Endosialin: a novel malignant cell therapeutic target for neuroblastoma", INT J ONCOL., vol. 39, no. 4, October 2011 (2011-10-01), pages 841
SAMBROOK ET AL.: "Molecular Cloning: A laboratory manual", 1989, COLD SPRING HARBOR LABORATORY PRESS, article "Expression of cloned genes in E. coli"
SASAKI TBRAKEBUSCH CENGEL JTIMPL R: "Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds b1 integrins, collagens and fibronectin", EMBO J, vol. 17, 1998, pages 1606 - 13
SETHI TRINTOUL RMOORE S ET AL.: "Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo", NAT MED, vol. 5, 1999, pages 662
T.HOLBROG.CIVENNIN.E. HYNES: "The ErbB receptors and their role in cancer progression", EXP CELL RES, vol. 284, 2003, pages 99 - 1 10
T.HOLBROR. BEERLIF. MAURER ET AL., THE ERBB2/ERBB3 HETERODIMER FUNCTIONS A SAN ONCOGENIC UNIT: ERBB2 REQUIRES ERBB3 TO DRIVE BREAST TUMOR CELL PROLIFERATION
TEICHER BA: "Newer vascular targets: endosialin (review", INT J ONCOL., vol. 30, no. 2, February 2007 (2007-02-01), pages 305 - 12
TOMKOWICZ BRYBINSKI KSEBECK DSASS PNICOLAIDES NCGRASSO LZHOU Y: "Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling", CANCER BIOL THER., vol. 9, no. 11, 1 June 2010 (2010-06-01), pages 908 - 15
ULLRICH ASURES ID.'EGIDIO MJALLAL BPOWELL TJHERBST RDREPS AAZAM MRUBINSTEIN MNATOLI C ET AL.: "The secreted tumor-associated antigen 90K is a potent immune stimulator", J BIOL CHEM, vol. 269, 1994, pages 18401 - 7, XP002914302
ULMER ET AL., JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 98, pages 1351 - 1366
ULMER TAKEELER VANDRE SGABIUS HJLOH LLAFERTE S: "The tumor-associated antigen 90K/Mac-2-binding protein secreted by human colon carcinoma cells enhances extracellular levels of promatrilysin and is a novel substrate of matrix metalloproteinases-2, -7 (matrilysin) and -9: Implications of proteolytic cleavage", BIOCHIM BIOPHYS ACTA, vol. 1800, no. 3, 2010, pages 336 - 343, XP026911646, DOI: 10.1016/j.bbagen.2009.07.030
ULMER TRICIA A ET AL: "Tumor-associated antigen 90K/Mac-2-binding protein: Possible role in colon cancer", JOURNAL OF CELLULAR BIOCHEMISTRY, A.R. LISS, vol. 98, no. 5, 1 August 2006 (2006-08-01), pages 1351 - 1366, XP002545567, ISSN: 0730-2312 *
UPDYKE TVNICOLSON GL: "Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential", CLIN EXP METASTASIS, vol. 4, 1986, pages 273 - 284
X. HUANGL. GAOS. WANG ET AL.: "Heterotrimerization of the growth factor receptors ErbB2. ErbB3, and Insulin-like growth factor- receptor in breast cancer cells resistant to Herceptin", CANE. RES.
Y YARDEN, THE EGFR FAMILY AND ITS LIGANDS IN HUMAN CANCER: SIGNALING MECHANISMS AND THERAPEUTIC OPPORTUNITIES
YANG JZHANG W: "New molecular insights into osteosarcoma targeted therapy", CURR OPIN ONCOL., vol. 25, no. 4, July 2013 (2013-07-01), pages 398 - 406
ZHANG DSJIANG WQLI SZHANG XSMAO HCHEN XQLI YHZHAN JWANG FH: "Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma", AI ZHENG, vol. 22, 2003, pages 870 - 3
ZHAO ANUNEZ-CRUZ SLI CCOUKOS GSIEGEL DLSCHOLLER N: "Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin TEM1 , using a paired yeast- display/secretory scFv library platform", J IMMUNOL METHODS, vol. 363, 2011, pages 221 - 232, XP027558132

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3995829A1 (fr) * 2020-11-09 2022-05-11 MediaPharma S.r.l. Lgals3bp en tant que biomarqueur diagnostique, pronostique et thérapeutique du covid-19 et autres maladies dues à un choc cytokinique
WO2022096732A1 (fr) * 2020-11-09 2022-05-12 Mediapharma S.R.L. Lgals3bp utilisé comme biomarqueur de diagnostic, de pronostic et thérapeutique dans la covid-19 et d'autres affections liées à un orage cytokinique

Also Published As

Publication number Publication date
EP3880706A1 (fr) 2021-09-22

Similar Documents

Publication Publication Date Title
KR101671378B1 (ko) ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
CA2813796C (fr) Anticorps se liant a erbb3
US20220218836A1 (en) Endosialin-binding antibody
EP0586002B1 (fr) Anticorps monoclonaux contre le récepteur du facteur épidermique de croissance, cellules et méthodes pour leur préparation et compositions qui les contiennent
US7910100B2 (en) Antibodies directed to the mammalian EAG1 ion channel protein
TWI443109B (zh) 抗ｅｐｈａ２抗體
CN112955471B (zh) Cd3抗体及其药物用途
CN115551889A (zh) 抗cd73抗体及其用途
WO2022068810A1 (fr) Anticorps bispécifique anti-claudine 18.2 et cd3 et son utilisation
KR20130012936A (ko) 암 예방 또는 치료용 약학적 조성물
CN109071671B (zh) Erbb2靶向抗体
EP3880706A1 (fr) Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3
Lee et al. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities
US11186632B2 (en) Methods of treating cancer using bifunctional molecules that target growth factors
CN114685674B (zh) 一种抗体融合蛋白及其应用
CA2116753C (fr) Anticorps monoclonaux reconnaissant le recepteur du facteur de croissance epidermique (egf), celluces et methodes de production et compositions contenant ces anticorps
JPWO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
CN116802297A (zh) 抗PD-L1/TGF-β双功能抗体及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19805555

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019805555

Country of ref document: EP

Effective date: 20210614